Harnessing ctDNA in Advanced Melanoma: A Promising Tool for Informed Clinical Decisions
Cutaneous melanoma, an aggressive malignancy, has undergone significant transformation in clinical management with the introduction of immune checkpoint inhibitors (ICIs) and targeted therapies. Current monitoring methods, such as imaging scans, present limitations, prompting exploration of alternat...
Main Authors: | Rugile Pikturniene, Alvydas Cesas, Sonata Jarmalaite, Arturas Razbadauskas, Vincas Urbonas |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2024-03-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/16/6/1197 |
Similar Items
-
Detectable ctDNA at the time of treatment cessation of ipilimumab and nivolumab for toxicity predicts disease progression in advanced melanoma patients
by: Lydia Warburton, et al.
Published: (2023-12-01) -
Utility of ctDNA Liquid Biopsies from Cancer Patients: An Institutional Study of 285 ctDNA Samples
by: Josep Gumà, et al.
Published: (2022-11-01) -
Corresponding ctDNA and tumor burden dynamics in metastatic melanoma patients on systemic treatment
by: Michael E. Egger, et al.
Published: (2024-04-01) -
The Role of ctDNA in Gastric Cancer
by: Justin Mencel, et al.
Published: (2022-10-01) -
The Use of ctDNA for <i>BRAF</i> Mutation Testing in Routine Clinical Practice in Patients with Advanced Melanoma
by: Paweł Sobczuk, et al.
Published: (2022-02-01)